MARKET

BLRX

BLRX

BioLine RX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.900
-0.180
-5.84%
After Hours: 2.900 0 0.00% 16:00 03/03 EST
OPEN
3.130
PREV CLOSE
3.080
HIGH
3.130
LOW
2.830
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.061
MARKET CAP
123.35M
P/E (TTM)
-1.5873
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Biolinerx (BLRX) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Biolinerx (BLRX), with a price target of $5.00. The company's
SmarterAnalyst · 5d ago
Penny Stocks Surge In February, 3 Cheap Stocks To Watch Now
Penny Stocks · 6d ago
Biolinerx (BLRX) Gets a Buy Rating from Oppenheimer
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Biolinerx (BLRX), with a price target of $10.00. The
SmarterAnalyst · 02/24 10:02
H.C. Wainwright Remains a Buy on Biolinerx (BLRX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRX) yesterday and set a price target of $19.00. The company's shares
SmarterAnalyst · 02/24 07:15
DJ BioLine RX Price Target Cut to $19.00/Share From $22.00 by HC Wainwright & Co.
Dow Jones · 02/23 16:34
DJ BioLine RX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/23 16:34
--Analyst Actions: HC Wainwright Adjusts BioLineRx' Price Target to $19 from $22, Keeps Buy Rating
MT Newswires · 02/23 12:47
BioLineRx Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 23, 2021 / BioLineRx Ltd. (NASDAQ:BLRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 10:00 AM Eastern Time.
ACCESSWIRE · 02/23 12:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLRX. Analyze the recent business situations of BioLine RX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLRX stock price target is 11.33 with a high estimate of 19.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 2.08M
% Owned: 4.90%
Shares Outstanding: 42.53M
TypeInstitutionsShares
Increased
3
35.70K
New
13
-2.23M
Decreased
5
37.50K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.13%
Pharmaceuticals & Medical Research
-1.98%
Key Executives
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Chief Scientific Officer
Merril Gersten
Vice President
Ella Sorani
Vice President
Moshe Phillip
Vice President
Abi Vainstein-Haras
Vice President - Business Development
David Malek
Vice President - Business Development
Hillit Mannor Shachar
Director
Michael Anghel
Director
Barbara-Jean Bormann
Director
Raphael Hofstein
General Manager
Leah Klapper
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Director
Jacob Friedman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers kinds of BioLine RX Ltd stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.